November 06, 2017
1 min read

Meta-analysis links proton pump inhibitors to kidney disease

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

We were unable to process your request. Please try again later. If you continue to have this issue please contact

A recent meta-analysis presented at ASN Kidney Week 2017 has linked certain medications commonly used to treat heartburn, acid reflux, and ulcers with the development of kidney disease.

Charat Thongprayoon, MD, from Bassett Medical Center, and his colleagues conducted an analysis of published studies that reported the risk of chronic kidney disease or kidney failure among proton pump inhibitor users compared with non-users.

Five studies with 536,902 participants met the eligibility criteria and were included in the meta-analysis. Individuals who used PPIs had a 33% increased relative risk of CKD or kidney failure when compared with non-users.

“This study demonstrates a significant association between the use of PPIs and increased risks of chronic kidney disease and kidney failure,” said Thongprayoon. “Although no causal relationship has been proven, providers should consider whether PPI therapy is indicated for patients. Chronic use of PPIs should be avoided if not really indicated.” - by Rebecca Zumoff